Filter By:
Viewing 1 to 10 (30 Total)

Binimetinib

01/20/2018

2018 Gastrointestinal Cancers Symposium (ASCO GI)

Phase 1b/2 Study of Binimetinib in Combination With Nivolumab (NIVO) or NIVO Plus Ipilimumab in Patients With Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer With RAS Mutation

J. Bendell, et al.

Binimetinib

09/10/2017

European Society for Medical Oncology Annual Congress

Quality of Life in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

H. J. Gogas, et al.

Binimetinib

09/10/2017

European Society for Medical Oncology Congress

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

A. Arance, et al.

Binimetinib

09/09/2017

European Society for Medical Oncology Congress

BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAFV600E Metastatic Colorectal Cancer (mCRC)

S. Huijberts, et al.

Binimetinib

06/03/2017

American Society of Clinical Oncology Meeting

Phase 1b/2 Trial of Ribociclib + Binimetinib in Metastatic NRAS-Mutant Melanoma: Safety, Efficacy, and Recommended Phase 2 Dose

Martin Schuler, et al.

Binimetinib

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Management of MEK inhibitor (MEKi) Toxicities of Binimetinib (BINI) in the NEMO Trial

P. A. Ascierto, et al.

Binimetinib

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Efficacy of Binimetinib in Patients with NRAS-mutant Melanoma: Subgroup Analysis of the Phase 3 NEMO Study

A. Arance, et al.

Binimetinib

06/06/2016

American Society of Clinical Oncology Meeting

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

R. Dummer, et al.

Binimetinib

09/28/2015

European Cancer Congress

A Phase 1b/2 Study of Ribociclib (LEE011; CDK4/6 inhibitor) in Combination With Binimetinib (MEK162; MEK inhibitor) in Patients With NRAS‐Mutant Melanoma

C. van Herpen, et al.

Binimetinib

09/27/2015

European Cancer Congress

LOGIC2: Phase 2, Multi-center, Open-label Study of Sequential Encorafenib/Binimetinib Combination Followed by a Rational Combination with Targeted Agents After Progression, to Overcome Resistance in Adult Patients with Locally Advanced or Metastatic BRAF V600 Melanoma

R. Dummer, et al.